Celgene Corporation (CELG) Receives ‘Analyst’ Rating

Celgene Corporation (CELG) : 14 brokerage houses believe that Celgene Corporation (CELG) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Celgene Corporation (CELG). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 17 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.35.

Celgene Corporation (CELG) : The consensus price target for Celgene Corporation (CELG) is $141.79 for the short term with a standard deviation of $12.26. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $162, however, the pessimist price target for the company is $120.


Also, BTIG Research upgrades their rating on the shares of Celgene Corporation (NASDAQ:CELG). The current rating of the shares is Buy. Earlier, the shares were rated a Neutral by the brokerage firm. The rating by the firm was issued on August 4, 2016.

Celgene Corporation (NASDAQ:CELG): After opening at $106.13, the stock dipped to an intraday low of $105.44 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $107.71 and the buying power remained strong till the end. The stock closed at $107.35 for the day, a gain of 1.22% for the day session. The total traded volume was 3,487,408. The stocks close on the previous trading day was $106.06.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.